A phase II, open-label, multicenter study of the ALK inhibitor alectinib in an ALK plus non-small-cell lung cancer (NSCLC) US/Canadian population who had progressed on crizotinib (NP28761). Meeting Abstract

Industry Collaboration International Collaboration

cited authors

  • Gandhi, Leena, Shaw, Alice, Gadgeel, Shirish M., Riely, Gregory, Cetnar, Jeremy, West, Howard Jack, Camidge, D. Ross, Socinski, Mark A., Chiappori, Alberto, Mekhail, Tarek, Chao, Bo H., Borghaei, Hossein, Gold, Kathryn A., Zeaiter, Ali Hassan, Bordogna, Walter, Balas, Bogdana, Puig, Oscar, Henschel, Volkmar, Ou, Sai-Hong Ignatius, NP28761 Study Investigators

authors

Publication Date

  • May 20, 2015

webpage

published in

category

volume

  • 33

issue

  • 15

WoS Citations

  • 14

WoS References

  • 0